Videos

Dr Ana Velázquez Mañana introduces a second patient case, a 59-year-old Black man diagnosed with mNSCLC and an EGFR exon 20 insertion, and outlines first-line treatment selection for the patient.

Prithviraj Bose, MD introduces a polycythemia vera (PV) patient case featuring a 67-year-old man presenting with frequent headaches and dizziness.

Expert panelists react to the presented data on racial and socioeconomic disparities in biomarker testing for patients with mNSCLC, and align on ways to address and overcome these disparities.

A panel of experts considers which factors best inform selection of first-line ALK TKI therapy in patients with non–small cell lung cancer.

Comprehensive discussion on molecular testing strategies utilized in non–small cell lung cancer to help inform treatment decisions.

Robert J. Soiffer, MD, discusses the role of transplantation and relapse after transplant for patients with cancer.

Nitin Jain, MD, discusses future improvements he anticipates for autologous and allogeneic chimeric antigen receptor T-cell therapies for B-cell acute lymphoblastic leukemia and other hematologic malignancies.

Yuri E. Nikiforov, MD, PhD, discusses the reclassification of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, which has significantly influenced the thyroid cancer space.

Carolyn Owen, MD, discusses data from the phase 3 GLOW study which were presented at the 10th Annual Meeting of the Society of Hematologic Oncology.

Closing their discussion, the panel highlights unmet needs in the management of relapsed/refractory multiple myeloma and shares clinical pearls for community physicians.

Krina Patel, MD, MSc, presents the case of a 65-year-old woman with relapsed/refractory multiple myeloma, and the panel discusses the optimal sequencing of her treatment regimens.

Closing out his discussion on chronic graft-vs-host disease, Yi-Bin Chen, MD, looks to the future of GVHD treatment.

Yi-Bin-Chen, MD, discusses the effect of GVHD recurrence and multiple-organ involvement on treatment decisions.

A summary of the systemic treatment options available for steroid-refractory chronic GVHD.

A comprehensive overview of the various treatment options for chronic graft-vs-host disease.

Yi-Bin Chen, MD, describes acute and chronic GVHD, and details the typical symptoms and presentations.

Anna Jo Bodurtha Smith, MD, discusses background on her research regarding insurance-mediated disparities in gynecologic oncology.

With updated data for the usefulness of tivozanib, patients with recurrent clear cell renal carcinoma have an effective option for treatment in a treatment landscape previously without many treatment options.

Casey M. Cosgrove, MD, discusses research exploring precision medicine concepts for endometrial cancer treatment.

Casey M. Cosgrove, MD, discusses biomarker-guided treatment for endometrial cancer.

Dr Jason Porter introduces three recent retrospective observational studies on use of biomarker testing in mNSCLC, which identified racial and socioeconomic disparities in testing patterns.

Panelists continue their dialogue on common challenges and barriers to use of biomarker testing in NSCLC, and share potential strategies to optimize use of testing.

Lori Leslie, MD, discusses ongoing clinical trials that are exploring chimeric antigen receptor T-cell therapy for the treatment of B-cell malignancies.

An expert on graft-vs-host disease provides an overview of GVHD prophylaxis and conditioning regimens prior to transplant.

Yi-Bin Chen, MD, an expert clinician and researcher, reviews a case study of a patient with GVHD and offers his initial impressions.

Gene G. Finley, MD, discusses some of the treatment options that have been used in the small cell lung cancer space, including intensive chemotherapies and targeted agents.

Nicholas J. Robert, MD, discusses the poster on the MYLUNG Consortium that he presented at the 2022 American Society of Clinical Oncology Annual Meeting.

Shared insight on a patient case of ALK+ non–small cell lung cancer with CNS metastasis and the role of brain MRIs in clinical practice.

Chandler Park, MD shares clinical insights regarding care for patients with renal cell carcinoma, touching on treatment selection and managing adverse effects.

Thoughtful discussion of ongoing clinical trials in the renal cell carcinoma landscape, with a particular focus on their eventual clinical implications.